MedPath

effect of latanoprost and travoprost on keratoconjunctiva l tissue

Not Applicable
Conditions
glaucoma
Registration Number
JPRN-UMIN000001477
Lead Sponsor
public health research foundation
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
240
Inclusion Criteria

Not provided

Exclusion Criteria

1. the eyes with chronic or recurrent uveitis, scleritis, corneal herpes infection 2. the eyes with the history of trauma, intraocular surgery, or Laser surgery within 6 months 3. the eyes with difficulty for the measurement of IOP with the applanation tonometer 4. the subjects with the allergy for PG-analogues or benzalconium chloride 5. the subjects using the eyedrops excluding those in this study 6. the subjects treated with oral carbonic anhydrase inhibitor 7. the subject with Sjogren syndrome 8. the subjects who can not drop periodically 9. the subjects with the advanced glaucoma or the terminal stage of glaucoma 10. the subjects with the severe ocular complications

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
the damage of corneal and conjunctival epithelium, and conjunctival hyperemia at 1 and 3 months after application of 2 kinds of IOP-lowering eye drops including a different preservative in each solution
Secondary Outcome Measures
NameTimeMethod
the change of intraocular pressure at 1 and 3 months after application of 2 kinds of IOP-lowering eye drops including a different preservative in each solution
© Copyright 2025. All Rights Reserved by MedPath